Effects of combined or sequential use of As2O3 and ATRA on survival time of SCID mouse–NB4 cell ascites model
| Protocol no. . | Sample no. . | Mean survival (d ± SD) . | % Prolongation compared with control . |
|---|---|---|---|
| A | 15 | 21.2 ± 1.6 | |
| B | 15 | 29.6 ± 3.5 | 39.9%* |
| C | 9 | 28.6 ± 3.1 | 35.2%* |
| D | 11 | 36.4 ± 5.1 | 71.9%* |
| E | 12 | 38.5 ± 4.8 | 81.9%* |
| F | 11 | 18.8 ± 6.5 |
| Protocol no. . | Sample no. . | Mean survival (d ± SD) . | % Prolongation compared with control . |
|---|---|---|---|
| A | 15 | 21.2 ± 1.6 | |
| B | 15 | 29.6 ± 3.5 | 39.9%* |
| C | 9 | 28.6 ± 3.1 | 35.2%* |
| D | 11 | 36.4 ± 5.1 | 71.9%* |
| E | 12 | 38.5 ± 4.8 | 81.9%* |
| F | 11 | 18.8 ± 6.5 |
Protocol numbers A, B, and C correspond to normal saline, As2O3 (8 mg/kg) or tRA (10 mg/kg) injected intraperitoneally (IP), once every 2 days, totally 10 times, respectively; protocol D: As2O3 (8 mg/kg) was used first once every 2 days, totally 8 times, followed by tRA (10 mg/kg) injected IP once every 2 days, totally 8 times; protocol E, tRA (10 mg/kg) was used first once every 2 days, totally 8 times, followed by As2O3 (8 mg/kg) injected IP once every 2 days, totally 8 times; protocol F: As2O3(8 mg/kg) combined with tRA (10 mg/kg) was injected IP once every 2 days, totally 10 times.
P < .01.